Skip to main content
. 2020 Oct;9(10):6116–6127. doi: 10.21037/tcr-20-1362

Table 1. Clinicopathological features of patients with diffuse large B cell lymphoma (DLBCL) stratified by body mass index (BMI).

Variables BMI, kg/m2 P
<27 (N=70) ≥27 (N=15)
Age in years; mean ± SD 65.1±16.9 55.2±12.0 0.034*
Males (%) 41 (58.6) 9 (60.0) 0.919
Performance status 0-1a; n (%) 53 (75.7) 13 (86.7) 0.503
LDHb level in U/L; mean ± SD 245±253 416±500 0.232
LDH level higher than normal (%) 32 (47.8) 10 (71.4) 0.145
β2-microglobulin, ng/mL; mean ± SD 3,170±2,099 2,882±1,998 0.676
Albumin, g/dL; mean ± SD 3.4±0.8 3.6±0.7 0.285
White cell count, ×109/L; mean ± SD 7.7±3.0 6.3±2.1 0.088
Hemoglobin, g/dL; mean ± SD 11.7±1.9 12.8±2.8 0.150
Platelet count, ×109/L; mean ± SD 248±103 176±78 0.013*
IPIc score; mean ± SD 2.22±1.39 2.13±1.51 0.823
NCCN IPId score; mean ± SD 3.51±1.88 3.47±1.81 0.939
NCCN IPI high-intermediate & high risk; n (%) 30 (44.8) 8 (53.3) 0.548
Extranodal involvemente; n (%) 35 (50.0) 6 (40.0) 0.482
Cell of origin; n (%) 0.122
   Germinal center B-cell like 23 (37.7) 2 (14.3)
   Non-germinal center B-cell 38 (62.3) 12 (85.7)
MYC expression on IHCf stain; n (%) 0.157
   Lowg 62 (92.5) 12 (80.0)
   Highg 5 (7.5) 3 (20.0)
BCL2 expression on IHCf stain; n (%) 0.005*
   Lowh 60 (89.6) 9 (60.0)
   Highh 7 (10.4) 6 (40.0)
BCL2 and MYC expression on IHCf stain; n (%) 0.013*
   BCL2low and MYClow 54 (83.1) 8 (53.3)
   BCL2high and/or MYChigh 11 (16.9) 7 (46.7)

a, ECOG performance status; b, LDH: lactate dehydrogenase; c, IPI: international prognostic index; d, NCCN-IPI: National Comprehensive Cancer Network International Prognostic Index; e, extranodal involvement of either BM, CNS, GI/liver, or lung; f, IHC stain: immunohistochemical stain; g, MYC expression: low: positive stain in <40% of cells; high: positive stain in ≥40% of cells; h, BCL2 expression: low: positive stain in <50% of cells; high: positive stain in ≥50% of cells. *, P value with significance.